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ABSTRACT  52 
Background: Metabolic syndrome (MetS) is defined by at least three of the following: blood 53 
pressure ≥ 130/85mmHg, fasting blood glucose ≥ 5.6mmol/L, triglycerides concentration ≥ 54 
1.7 mmol/L, waist circumference ≥ 102 cm (for men), and high-density lipoprotein 55 
cholesterol concentration < 1.03mmol/L (for men). MetS has been associated with worse 56 
lower urinary tract symptoms (LUTS) and higher International Prostate Symptom 57 
questionnaire scores.  58 
Materials and Methods: Medical Literature Analysis and Retrieval System online (MEDLINE), 59 
Cochrane, ClinicalTrials.gov and SCOPUS were critically appraised for all peer-reviewed 60 
manuscripts that suitably fulfilled our protocol’s inclusion criteria established a priori. Meta-61 
analytical and meta-regression calculations were performed in R using the Sidik Jonkman 62 
Hartung Knapp random effects model and predefined covariates. 63 
Results: A total of 70 studies (n = 90206) were included in qualitive synthesis. From these, 64 
60 studies focused on MetS and LUTS: 44 reported positive correlations; 5 reported negative 65 
correlations; 11 reported no association; 10 studies focused on MetS and total prostate 66 
volume (TPV). MetS positively correlated with moderate LUTS (OR 1.56, 95% CI 1.35–1.80), 67 
severe LUTS (OR 2.35, 95% CI 1.82–3.03), OAB (OR 3.2, 95% CI 1.6-5.8), and nocturia severity 68 
(OR 2.509, 95% CI 1.571-4.007) at multivariate analysis. A total of 30 studies (n = 22206) 69 
were included in meta-analysis; MetS was significantly associated with higher TPV (mean 70 
difference 4.4450 ml; 95% CI 2.0177, 6.8723, but no significant predictive factors for effect 71 
sizes were discovered. 72 
Conclusion: Our meta-analysis demonstrates a significant association between the 73 
aggravating effects of metabolic syndrome, which commonly coexists with obesity and 74 
benign prostate enlargement.  75 
 76 
ABBREVIATIONS   77 
MetS, Metabolic Syndrome; LUTS, Lower Urinary Tract Symptoms; BOO, Bladder Outlet 78 
Obstruction; BPH, Benign Prostatic Hyperplasia; BPE, Benign Prostatic Enlargement; OAB, 79 
Overactive Bladder; DO, Detrusor Overactivity; UUI, Urgency Urinary Incontinence; SUI, 80 
Stress Urinary Incontinence; IC, Interstitial Cystitis; BPS, Bladder Pain Syndrome; IPSS, 81 
International Prostate Symptom Score; IPSS-T, International Prostate Symptom Score Total; 82 
IPSS-QOL, International Prostate Symptom Score Quality of Life; UVV, Uroflowmetry Voided 83 
Volume; Qmax, Uroflowmetry Qmax; PVR, Post-void Residual volume; PSA, Prostate-Specific 84 
Antigen; PV, Prostate Volume; TPV, Total Prostate Volume; TRUS, transrectal 85 
ultrasonography; DRE, digital rectal exam; BMR , Basal Metabolic Rate; BMI, Body Mass Index; 86 
WC, Waist circumference; HC, Hip Circumference; NC, Neck Circumference; WHR, Waist-87 
to-hip Ratio; HDL-C, High Density Lipoprotein-Cholesterol; LDL-C, Low Density Lipoprotein-88 
Cholesterol; FBG, Fasting Blood Glucose; FBS, Fasting Blood Sugar; TG, Triglycerides; HT, 89 
Hypertension; BP, Blood pressure; DM, Diabetes Mellitus; T2D, type II diabetes; IR, Insulin 90 
Resistance; HbA1c, Haemoglobin A1C; HOMA-I, Homeostatic model assessment Index; NCEP, 91 
The National Cholesterol Education Program; MEDLINE, Medical Literature Analysis and 92 
Retrieval System Online; CENTRAL, Cochrane Central Register of Controlled Trials; MeSH, 93 
Medical Subject Heading; NOS, Newcastle-Ottawa scale; NGF, Nerve Growth Factor; EjD, 94 
Ejaculatory Dysfunction; WHO, World Health Organisation; NHS, National Health Service; 95 
CDC, Centers for Disease Control and Prevention; HR, Hazard Ratio; OR, Odds Ratio; p, p-96 
value; t, t-value; QUIPS, Quality in Prognosis Studies; MD, pooled weighted mean 97 
differences. 98 
1. INTRODUCTION  99 
Metabolic syndrome (MetS) is defined as the presence at least three of the following: blood 100 
pressure (BP) ≥130/85 mmHg, fasting blood glucose (FBG) ≥5.6mmol/L, triglycerides (TG) 101 
concentration ≥1.7, waist circumference (WC) ≥102 cm for men and ≥89cm for women, and high-102 
density lipoprotein cholesterol (HDL-C) concentration <1.03mmol/L for men and <1.4mmol/L for 103 
women [1]. One of the major contributing factors to MetS is Obesity; the prevalence of those 104 
with obesity has almost since 1975 [2]. In England, it affects 28% of adults and it was directly 105 
associated with 1117 hospital admissions in 2018/19 [3,4].  106 
Body Mass Index (BMI) ≥35 kg/m2 has been positively correlated with moderate-severe 107 
lower urinary tract symptoms (LUTS) (OR 1.38, 95% CI 1.171.63) [5]; WC ≥42 inches 108 
(106.7cm) was also significant factor [6]. Additionally, low density lipoprotein-cholesterol 109 
(LDL-C) concentration >7.4mmol/L caused a fourfold increased risk of BPH (OR 4.00, 95% CI 110 
1.27-12.63, p = 0.02) [7]. LUTS encompass a variety of bladder conditions: benign prostatic 111 
hyperplasia (BPH); urinary tract infection (UTI); overactive bladder (OAB); nocturia; 112 
interstitial cystitis (IC); bladder pain syndrome (BPS). LUTS consists of storage symptoms 113 
(urinary incontinence, urgency, frequency, and nocturia), voiding symptoms (intermittency, 114 
slow stream, hesitancy, straining to void, terminal dribble, and splitting of stream), and 115 
post micturition symptoms (incomplete bladder emptying) [8], [9] Obesity and more 116 
specifically patients with a BMI ≥35 kg/m2 have been positively correlated with moderate-117 
severe LUTS (OR 1.38, 95% CI 1.171.63) [5],[7] LUTS leads to worsening quality of life, sleep, 118 
and mental health in men and women [9]. LUTS severity may be quantified by the 119 
International Prostate Symptom Score (IPSS) that looks mild, moderate, and severe 120 
symptoms [8]. 121 
This systematic review and meta-analysis aims to review all existing evidence on the 122 
association between MetS and in LUTS; more specifically, the effect of MetS on prostatic 123 
inflammation and subsequent hyperplasia in patients with LUTS and BPH.  MetS is a growing 124 
problem worldwide, and its role in LUTS is unclear; LUTS aetiology is not entirely 125 
understood. Whilst studies point towards an association between MetS and LUTS, several 126 
studies reported no association at multivariate analysis [10–13]. Our aim is to provide new 127 
insight and propose therapeutic targets for MetS and LUTS.  128 
2.  MATERIAL & METHODS  129 
The protocol was developed according to the Preferred Reporting Items for Systematic 130 
review and Meta-Analysis Protocols (PRISMA-P), and followed methods outlined in The 131 
Cochrane Handbook for Systematic Reviews of Interventions [14]. This systematic review 132 
has been registered with PROSPERO (International prospective register of systematic 133 
reviews) with registration number CRD42020223412. 134 
2.1  Search Strategy 135 
Two reviewers conducted systematic searches of the following databases: Medical Literature 136 
Analysis and Retrieval System Online (MEDLINE), SCOPUS, Cochrane Central Register of 137 
Controlled Trials (CENTRAL), and ClinicalTrials.gov databases. The following MeSH (Medical 138 
Subject Heading) terms were used: (((((metaflammation) OR (metabolic cells)) OR 139 
(mitochondrial dna)) OR (inflammaging)) OR (metabolic syndrome)) AND (((((lower urinary 140 
tract symptoms) OR (luts)) OR (urinary tract infection)) OR (uti)) OR (interstitial cystitis)). 141 
In addition, reference lists of selected articles and other literature sources were browsed 142 
to ensure a comprehensive literature search was completed. Searches filtered results based 143 
on year of publication date (last 10 years), and the last search was carried out on October 144 
24, 2020.  145 
2.2  Study Selection 146 
Studies were imported into Covidence (Covidence (Veritas Health Innovation, Melbourne, 147 
Australia; http://www.covidence.org)) [15]. All studies were screened for selection by two 148 
reviewers independently (of a group of five) and any conflicts were resolved by a third 149 
reviewer. Selection was completed in two stages – firstly by title and abstract and then by 150 
full text. Studies were selected using specific which removed duplicates. Five reviewers 151 
selected studies individually and once completed, a second reviewer selected the studies. 152 
A third reviewer resolved conflicts. Studies were screened for title and abstracts and then 153 
full text screened. Studies were included if they met the inclusion criteria: cohort studies, 154 
case control studies, randomised clinical trials, cross-sectional studies (no limit on sample 155 
size, setting, follow-up period, or intervention); men and/or women aged 18 or above; any 156 
component of MetS; any LUTS condition (e.g. LUTS/BPH, OAB, DO, UI); and original articles. 157 
Exclusion criteria: studies including children, pregnant women, bladder or prostate 158 
cancers/other forms of cancers or animal models; editorials, letters, case reports, opinion 159 
pieces, commentaries, systematic reviews and metanalyses; and articles not in English.  160 
2.3  Data extraction 161 
Five reviewers extracted data using Covidence (Covidence (Veritas Health Innovation, 162 
Melbourne, Australia; http://www.covidence.org)) [15]. A second reviewer checked the 163 
data extracted. Finally, the data were exported to Microsoft excel from Covidence. Example 164 
of columns: reference; country; study design; start date; end date; method to classify LUTS; 165 
type of LUTS; sample size; gender; population description; MetS criteria; outcome 166 
measured; summary of association of Mets and LUTS; quality assessment. Meta-analysis and 167 
meta-regression were conducted from February 2021 to 26th April 2021. 168 
2.4  Quality assessment 169 
Each study was assessed for bias using the Newcastle-Ottawa scale (NOS). Studies were 170 
evaluated on eight factors, categorised into three groups: selection (including whether the 171 
cohort is representative of the population), comparability (assessed on grounds of study 172 
design and the analysis performed) and outcome (i.e., the assessment of outcome, follow-173 
up rate, and adequacy of follow-up period). Stars were awarded per category, with a 174 
maximum of four, two and three stars possible for the ‘selection’, ‘comparability’ and 175 
‘outcome’ categories respectively [16]. Five reviewers assessed the studies to be of poor (3 176 
stars or less), fair (4-6 stars) or good (7-9 stars) quality (NOS). A risk of bias assessment using 177 
the Quality in Prognosis Studies (QUIPS) tool was also carried out for all 30 studies included 178 
in meta-analysis [17]. The QUIPS tool assessed study participation; study attrition; 179 
prognostic factor measurement; outcome measurement; study confounding; statistical 180 
analysis reporting; overall risk of bias.  181 
 182 
2.5  Data Synthesis and Statistical Analysis  183 
All meta-analytical calculations were carried out by an external statistician using R 184 
statistical software (v4.0.4) with meta package (v4.18-0). The drawn forest plots were 185 
contrived using this software. Pooled odds ratios (OR) were calculated with 95% confidence 186 
intervals (CI) from the extracted count data, whilst continuous data were used to calculate 187 
pooled weighted mean differences (MD) with 95% CI. Pooled MD with 95% CI  were calculated 188 
using the inverse variance method and random-effects model with Sidik—Jonkman 189 
estimation and Hartung—Knapp adjustment for random effects model. Presence of 190 
heterogeneity was tested using the χ2 test and quantified with the I2 statistic (I² > 75% 191 
considered significant). Heterogeneity was addressed by performing meta-regression 192 
analysis using mixed-effects model with predefined predictors (sample size, study rating, 193 
year of publication, and country of study). Meta-regression analysis was performed to 194 
address heterogeneity by checking for possible association of predefined factors (sample 195 
size, study rating, year of publication, and country of study) with effect size differences. 196 
Bubble plots were generated to visualise the results of meta-regression analysis. Odds ratios 197 
were used to compare the relative odds of LUTS in relation to MetS. OR < 1 suggests the 198 
intervention or exposure is associated with reduced odds of said outcome occurring. OR = 1 199 
suggests no association between the outcome and intervention. OR > 1 posits higher odds of 200 
an outcome occurring as anan association with an intervention [14]. Any potential 201 
publication bias was assessed with Eggers’ test of intercept and visual evaluation of the 202 
funnel plot.  203 
 204 
3. Results  205 
1741 studies were imported into Covidence, which removed 4 duplicates. Four reviewers 206 
screened 1737 studies for title and abstracts, and 1518 were excluded. Five reviewers 207 
screened the full text of the remaining 219 studies; 149 studies were excluded. 70 studies 208 
were included in qualitative synthesis and 30 in meta-analysis (Fig. 1). Three studies used 209 
the same patient cohorts and were excluded [18–20]. General characteristics of the included 210 
studies are presented in Table 1, while the outcomes measured and a summary of the 211 
association between MetS and LUTS are detailed in Table 2. A forest plot for TPV and MetS 212 













3 represents Meta-regression analysis (Bubble Plots) for age; study rating; publication year. 214 
The results of the Publication Bias assessment - Egger’s test of the intercept – are presented 215 
in Figure 4. Figure 5 represents a QUIPS Risk of Bias Assessment for the 30 studies included 216 
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Table 1 (i) General characteristics of studies included in systematic review  239 
Study  Country Study design MetS 
criteria 
Type of LUTS Method to assess 
LUTS 
Start date  End date  Sample 
size (n) 
Sex 
Akin 2016 [22]     Turkey Cohort NCEP  OAB  OAB-V8 Aug-2012 Dec-2013 204 Female 
Aktas 2011  [23]  Turkey Cohort US NCEP-
ATP III 
LUTS IPSS Jan-2009 Oct-2009 106 Male 
Barbosa 2013 [24]   Brazil Cohort IDF; AHA; 
NHLBI  
LUTS  IPSS 2012 2012 907 Male 




PRI Jan-2013 Mar-2014 120 Male 
Bray 2017 [26]   UK Cohort None 
given  
OAB ICIQ-FLUTS Not defined 212 Female 
Byun 2012 [27] 
 
Korea Retrospective  NCEP-ATP 
III; AHA; 
NHLBI 
BPH TRUS, PSA Jan-2005 Dec-2010 521 Male 
Choi 2013 [28] 
 




BPH TRUS, PSA Jan-2007 July-2011 4111 Male 




OAB OABSS May-2008 Nov-2008 1301 Male 
Coban 2014 [30]     Turkey Cohort IDF 2005 
criteria  
LUTS IPSS, QOL May-2012 Apr-2013 107 Male 
Dagdeviren 2018 [31]  Turkey Cohort IDF 2006 OAB OAB-V8 Jan-2015 Sep-2015 90 Female 
Demir 2009 [10]   Turkey Cross-sectional NCEP-ATP 
III 
LUTS IPSS-QOL  Not defined 
 
190 Male 
de Nunzio 2014 [32]    Italy Cohort ATP III LUTS IPSS  Jan-2009 Onward 431 Male 
de Nunzio 2017  [33]  Italy Cohort NCEP-ATP 
III 
LUTS IPSS, IIEF, MSHQ-EjD Jan-2012 Mar-2016 220 Male 
de Nunzio 2018 [34]   Italy Cross-sectional ATP III LUTS, nocturia IPSS Oct-2009 Onward 492 Male 
de Nunzio 2019 [35]   Italy Prospective cross-
sectional  
ATP III    IPPS 2015 Onward 227 Male 
Doğan 2015 [36]  Turkey Cross-sectional  NCEP-ATP 
III  
LUTS IPPS Not defined 
 
78 Male 
Eom 2011 [37]   South Korea Cross-sectional NCEP-ATP LUTS, 
nocturia 
IPSS Oct-2003 Feb-2010 33841 Male 
Eren 2019 [38]   Turkey Retrospective cohort IDF  LUTS IPSS Jan-2016 Mar-2018 356 Male 
Fu 2016 [39]    China Prospective cohort NCEP-ATP 
III for Asian 
Americans 
UI, UTI, LUTS IPSS Apr-2013 Apr-2016 1007  Male 
Gacci 2013  [40]  Italy Retrospective cohort IDF; AHA; 
NHLBI 
LUTS   IPSS, IS Jan-2010 Sep-2011 271 Male 









Gao 2012  [13]  China Cross-sectional  2005 
NCEP-ATP 
III 
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Table 1 (ii) General characteristics of studies included in systematic review continued  241 
















Sex Population description NOS 
rating 
Haghshe














976 Male Random selection using national 
population registers. Swedish 
study population of 3014 men, 
aged 69–80 years, from three 


















1506 Male Korean men between 30 and 60 
years, excluded men with 
prostatitis, high PSA or abnormal 


















102 Female Women with T2D at diabetic clinic 













LUTS IPSS 2012 2014 4256 Male Healthy native Korean men aged 
40-65 years who voluntarily 
underwent a medical checkup 
9-Good 
Kupelian 
2013  [46]  
USA Randomised 
control trial 























151 Male Patients who underwent HoLEP for 
BPO. Patients received BPH 
medication at least 6 months prior 
to surgery. 
9-Good 
Lai 2019  













920  Male, 
Female 
Patients > 18 years who presented 
to a urologist or urogynaecologist 
for treatment of LUTS: 456 males 
















409 Male Men aged > 40 years with 
moderate-severe LUTS with no 
previous treatment; divided into 











LUTS  IPSS 2004 Onward 1520 Male Resident within the borders of the 
survey area ≥ 6 months. Study on 
328 men (aged 50-89 years) 
























Male Male patients attending infertility 






Australia Cohort Not 
defined 
LUTS IPSS Not defined 1103 Male Males aged 35–80 residing in the 
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Not defined 58 Male LUTS group: patients with IPSS ≥8 















40 Female Women aged 50-80 years with 
clinical diagnosis of OAB 











94 Male Male, 50-65 years of age, prostate 























900 Male Japanese men who had 
participated in a general health 














1031 Men Japanese men who visited the 





















400  Female Women who visited Okmeydani 
Training and Research Hospital. 













93 Male BPH patients with LUTS ≥50 years 
who visited urology outpatient 
clinic. Median age: 60 years. 























Table 1 (iii) General characteristics of studies included in systematic review continued  243 































137  Male, 
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Examination Center for a 
regular health checkup in 
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4880 Male Men post TURP with average 
age 54.1±8.6 years 
9-Good 
Pashoot
an 2015  
[66] 







4666 Male 379 GPs randomly selected in 
France who included all male 
patients aged 55–100 years seen 













2010 2011 616 Male All male patients aged ≥ 40 
years who attended outpatient 
urology clinic from 2010 to 2011 
9-Good 
Russo 
2014  [68]  
Italy Cross-
sectional  
































264 Male 13.8% (32/232) patients affected 
by MetS, 13.8% (32/232) affected 
by NAFLD, 42.7% (99/232) 
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Italy Cross-
sectional  











2017 [72]      
Croatia Case-
control 






57 MetS (27 men and 30 women) 














354 Male 74 patients with IPSS 0-7; 97 
patients with IPSS 8-19; 66 















313 Female 30-70 years, female patients 
who applied to the policlinics 
with OAB symptoms or other 
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132 Male Patients affected by moderate-
severe LUTS due to BOO, 
secondary to clinical BPH, and 











506 Male Men > 45 years who underwent 
routine physical examinations 
















708 Male Men ≥ 45 years (mean, 
55.6±9.72 years) who 
voluntarily underwent a self-
paid medical checkup at the 
Health Management Center of 






Taiwan Cohort NCEP-ATP 







616 Male Males ≥ 40 years recruited from 
a self-paid medical check-up at 
the Health Management Center 
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Table 1 (iv) General characteristics of studies included in systematic review continued  246 















Sex Population description NOS 
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1176  Male Male subjects ≥ 18 years, 
referred to a tertiary centre 
urology clinic for LUTS, elevated 
PSA or haematuria. 966/1176 
included 
8-Good 











764 Male Males who lived in Kaohsiung city 



















968 Male Men aged 30-49 years who 
underwent TRUS of prostate for 















92 Male,  
Female 
Prospective multicentre clinical 
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840 Female Out of 840 enrolled, 704 had 
OAB, 305 had DO, 88 had stress 
UI, 26 had recurrent UTIS, 12 had 











LUTS IPSS Not defined 
 
490 Male Unselected and consecutive 490 
male adults (mean age 58±9 












401 Male BPH patients older than 60 years 9-Good 
Zhao 
2016a  
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551 Male Aged ≥ 45 years with moderate-
severe LUTS due to BPE recruited 













LUTS  IPSS Not defined 
 
807 Male Men aged 46-89 with LUTS due to 
BPE (PV>30 mL and IPSS >7)  
5-Fair 
 247 
Abbreviations: MetS, Metabolic Syndrome; OAB, Overactive Bladder; LUTS, Lower Urinary Tract Symptoms; BPH, Benign Prostatic Hyperplasia; 248 
UUI, Urinary Urgency Incontinence; SUI; Stress Urinary Incontinence; BOO, Bladder Outlet Obstruction; BPO, Benign Prostatic Obstruction; TURP, 249 
Transurethral Resection Of The Prostate; DO, Detrusor Overactivity; rUTI, recurrent Urinary Tract Infection; BPS, Bladder Pain Syndrome; OAB-250 
V8, Overactive Bladder-Validated 8-Question awareness tool; IPSS, International Prostate Symptom Score; IPSS-QOL, International Prostate 251 
Symptom Score Quality of Life; PRI, Prostatic Resistive Index; ICIQ-FLUTS, International Consultation on Incontinence Questionnaire-Female Lower 252 
Urinary Tract Symptoms; OABSS, Overactive Bladder Symptom Score; IIEF, International Index of Erectile Function; IIEF5, Internal Index Of Erectile 253 
Function-5; IIEF, International Index of Erectile Function; MSHQ-EjD, Male Sexual Health Questionnaire ejaculatory dysfunction; IS, Inflammatory 254 
Score; PSA, Prostate-Specific Antigen; PV, Prostate Volume; AUA-SI, American Urological Association Symptoms Index; IUSS, Indevus Urgency 255 
Severity Scale; PVR, Post-Void Residual Volume; Qmax, Peak urinary flow; TRUS, Transrectal Ultrasound; HoLEP,  Holmium Laser Enucleation of 256 
the Prostate; ICIQ, International Consultation on Incontinence Questionnaire; IIQ-7, Incontinence Impact Questionnaire; NIHCPSI, National 257 
Institutes of Health Chronic Prostatitis Symptom Index; ADAM, Androgen Deficiency In Aging Males; PEDT, Premature Ejaculation Diagnostic Tool; 258 
AMS, Aging Male Symptom scale; DRE,  Digital Rectal Examination; PPIUS, Patient Perception of Intensity of Urgency Scale; KHQ, King’s Health 259 
Questionnaire; NOS, Newcastle-Ottawa scale; T2D, Type II diabetes. NCEP, The National Cholesterol Education Program; ATP III,  Adult  Treatment 260 
Panel III; IDF, International Diabetes Federation; AHA, American Heart Association; NHLBI, National Heart, Lung, and Blood Institute; WHO, World 261 
Health Organization; JASSO, Japan Society for the Study of Obesity; WHF, World Heart Federation;  IAS, International Atherosclerosis Society; 262 
IASO, International Association for the Study of Obesity; SEMT, Society of Turkish Endocrinology and Metabolism; MHLW, Japan's Ministry of Health 263 




Fig. 2 Forest plot for TPV and MetS. Number of studies combined: k = 30 (n= 22206). MD = 4.4450; 95% CI [2.0177; 6.8723]; t 
3.75; p = 0.0008. Quantifying heterogeneity: tau2 = 37.0851 [18.9614; 71.7320]; tau = 6.0898 [4.3545; 8.4695].  I2 = 96.3% 
[95.4%; 96.9%]; H = 5.17 [4.67; 5.72]. Test of heterogeneity: Q 774.09; degrees of freedom, d.f. 29; p < 0p < 0.0001. Details 
on meta-analytical method: Inverse Variance method; Sidik—Jonkman estimator for tau2; Q-profile method for confidence 




















Fig. 4 Publication Bias assessment. Egger’s test of the intercept: intercept 1.073; 95% CI -1.71 - 3.86; t = 0.754; p = 0.4570147. 












Fig. 5 QUIPS Risk of Bias Assessment graph for the 30 studies included in meta-analysis. Risk of bias for the following 
components: study participation; study attrition; prognostic factor measurement; outcome measurement; study 
 
 







Overall risk of bias
Low risk of bias Moderate risk of bias High risk of bias Not applicable
 
 
Table 4 QUIPS Risk of Bias Assessment table for each study included in meta-analysis (k=30). Risk of bias for following 
components: study participation; study attrition; prognostic factor measurement; outcome measurement; study confounding; 
statistical analysis reporting; overall risk of bias. 
 
















Coban 2014  [30] Low NA Low Moderate High Moderate High 
de Nunzio 2014 
[32]    Moderate NA Low Low High Low High 
de Nunzio 2017 
[33]  Moderate Low Low Low Moderate Low Low 
de Nunzio 2019 
[35]   Moderate NA Low Moderate Moderate Low Moderate 
Fu 2016 [39]    Moderate Low Low Low High Moderate High 
Gacci 2013  [40]  Low NA Low Low Moderate Low Low 
Gacci 2017 [41]   Low NA Low Low Moderate Low Low 
Kim 2014 [45]   Moderate NA Low Low High Low High 
Kwon 2017  [47] Moderate NA Low Low High Low High 
Nandy 2016 [54] High NA Low Low High High High 
Pan 2014 [59] Moderate NA Low Low Low Low Low 
Park 2013  [62] Moderate NA Low Low Moderate Low Low 
Park 2018  [64] Moderate NA Moderate Low High Low High 
Russo 2018 [71] Low NA Low Low High Low High 
Vanella 2014 [74]   Moderate NA Low Moderate High Low High 
Yang 2012  [76] Moderate NA Low Low Moderate Moderate Moderate 
Zamuner 2014 
[83]   Moderate NA Low Low High Low High 
Zhang 2014 [84] Moderate NA Low Low High Moderate High 
Zhao 2016a  [85]   Moderate NA Low Low Moderate Low Moderate 
Zhao 2016b [86]   Moderate NA Low Low High Low High 
Byun 2012 [27] Moderate NA Low Low High Moderate High 
Choi 2013 [28] Moderate NA Low Low Low Low Low 
Yoon 2016 [81] Moderate NA Low Low Low Low Low 
Ozden 2007 [58] Moderate NA Low Low High High High 
Xia 2019 [75] Moderate NA Low Low Low Moderate Low 
Zorba 2017 [87]  Moderate NA Low Low High Moderate High 
Park 2008 [61] Low NA Low Low High Low High 
Yim 2011 [80]  Low NA Low Low High Low High 
Jeong 2011 [43] Low High Low Low High Low High 
Lotti 2014 [50] Low High Low Low High Low High 
3.2 Summary of qualitative data 
A total of 70 studies were included in qualitive synthesis. From these, 60 studies focused on 
MetS and LUTS: 44 reported positive correlations; 5 reported negative correlations; 11 
reported no association; 10 studies focused on MetS and total prostate volume (TPV) (Table 
2). MetS positively correlated with moderate LUTS (OR 1.56, 95% CI 1.35–1.80; p < 0.001), 
severe LUTS (OR 2.35, 95% CI 1.82–3.03; p < 0.001) [66], OAB (OR 3.2, 95% CI 1.6-5.8, p = 
0.01) [44], and nocturia severity (OR 2.509, 95% CI 1.571-4.007, p = 0.001) [34] at 
multivariate analysis. Demir et al. (2009) reported positive correlations between MetS and 
LUTS (OR 2.4, 95% CI 1.24–4.59, p = 0.009) [10]; however, significance was lost at multiple 
logistic regression analysis. Baykam et al. (2015) found no association between LUTS and 
BMI (kg/m2); only FBG was significant at multivariate analysis (β = 0.001, t = 3.491, p = 
0.001) [25]. Gao et al. (2012) found that MetS was not associated with the severity of LUTS 
(multivariate: OR 0.97; 95% CI 0.67-1.39) [13].  
3.3 Summary of meta-analysis 
Initially, data from 70 studies was extracted and a meta-analysis on MetS and LUTS, which 
included 33 studies, was conducted; this generated 16 forest plots. the following outcomes 
vs. MetS were evaluated: IPSS-T; IPSS voiding; IPSS storage; IPSS-QOL; TPV (ml); Prostate-
Specific Antigen (PSA) (ng/ml); uroflowmetry Qmax (ml/s); Post-void residual volume (PVR) 
(ml). Furthermore, forest plots for IPSS severity and each MetS component were generated; 
results were not significant; however, heterogeneity was relatively low in some plots. Given 
that TPV proved significant, we explored this further and systematically searched for studies 
on TPV and MetS (10 additional studies were identified). We generated another forest plot 
for TPV and MetS (total of 30 studies), which proved highly significant, albeit heterogeneity 
was high: I2 96.3% [95.4%; 96.9%]. Results are presented in Fig. 2. Due to the high 
heterogeneity, a meta-regression analysis was performed to test the impact of covariates 
on heterogeneity. Meta-regression analysis was performed for predictors: age; country; 
study rating; publication year; results were not significant (p > 0.05) therefore, predictors 
had no effect on heterogeneity (Fig. 3; Table 3). An Egger's test of the intercept was 
performed to test for publication bias; the test revealed a symmetric inverted funnel shape 
indicating a ‘well-behaved’ data set, in which publication bias is unlikely (intercept 1.073; 
95% CI: -1.71-3.86; t = 0.754; p = 0.4570147) (Fig. 4). A Risk of Bias assessment was also 
performed, as shown in Fig. 5 and Table 4, with an overall high risk of bias in most studies.  
4. DISCUSSION  
Associations between LUTS and MetS have long since been contentious with clinical 
mechanisms and remain poorly understood. This meta-analysis sought to review all current 
published data in order to highlight any significant findings to date. Our meta-analysis (k = 
30, n = 22206) on TPV and MetS indicated significant results confirmed a significant 
association (MD = 4.4450, 95% CI [2.0177; 6.8723], t = 3.75; p = 0.0008). However, 
heterogeneity was high (tau2 = 37.0851 [18.9614; 71.7320], I2 = 96.3% [95.4%; 96.9%], H = 
5.17 [4.67; 5.72]). Meta-regression produced non-significant results suggesting that 
predictors (age; country; study rating; publication year) had no effect on heterogeneity. 
Our study found no association between MetS and IPSS or its subgroups, PSA, Qmax, and 
PVR. Several studies have demonstrated that MetS causes inflammation and prostatic 
hyperplasia in men with BPH/LUTS. The results of our meta-analysis are consistent with 
other literature. Zou et al. (2016) conducted a meta-analysis on 16 studies (BPH patients, n 
= 1895) on MetS and BPH in Chinese patients; total prostate volume (MD = 10.15 ml; 95% CI 
7.37-12.93) and annual prostate growth rate (MD = 0.49 ml/year; 95% CI 0.24-0.73) were 
significantly higher in BPH patients with MetS compared to patients without MetS  [88]. A 
meta-analysis by Gacci et al. (2015) reported similar findings; total prostate volume was 
significantly higher in BPH patients with MetS (+1.8 mL, 95% CI 0.74-2.87, p < 0.001). 
Additionally, no association was found between MetS and IPSS [89]. Wu et al. (2019) also 
reported a significant between MetS and total prostate volume (OR 2.34, 95% CI 1.25–3.42) 
after performing a meta-analysis on 6 comparative studies (n = 61826). Again, similar to our 
study, Wu et al. found no significant association was found between MetS and IPSS or PVR  
[90]. Wang et al. (2016) (k = 8, n = 3093) reported that BPH patients with MetS had 
significantly higher prostate growth rates (MD = 0.67 mL/y, p < 0.001) and prostate volumes 
(MD = 6.8 mL, p = 0.010). No significant association between MetS and IPSS, and Qmax; 
however, there was an almost significant association with PSA (MD = 0.24 ng/mL, p = 0.056) 
[91]. Li et al. (2020) also significantly associated MetS with higher annual prostate growth 
rate and prostate volume; no association between MetS and IPSS/IPSS subgroups. In contrast 
to our study, Li et al. significantly associated MetS with reduced Qmax (MD = -0.48, p = 
0.001) and increased PVR (MD = 8.28; p < 0.001) [92]. Russo et al. (2015) demonstrated that 
a significant association between MetS and prostate volume (MD = 2.18; p = 0.03); no 
association with IPSS [93]. Differences in results may be due to the number and type of 
studies included in meta-analysis. Our meta-analysis included retrospective, cross-sectional 
studies, and randomised control trials (k = 30, n = 22206); not all studies used TRUS to 
measure total prostate volume. Wu et al. (2019) included retrospective studies and one 
prospective study (k = 6, n = 61826); studies used TRUS; one study used suprapubic 
ultrasound [90]. Wang et al. (2016) included cohort or case-control studies (k = 8, 3093), all 
of which used ultrasound or TRUS; heterogenity (I2) was also high (90.1%) [91]. Li et al. 
(2020) included prospective and retrospective studies (k = 21, n = 15317); 17 studies used 
TRUS to measure total prostate volume. Forest plot results indicated a significantly lower 
heterogenity of 49%, whilst our heterogenity was 96% [92]. Russo et al. (2015) (k = 19, n = 
18476) included 6 studies in the forest plot for prostate volume and heterogenity was 85%; 
BPH definitions varied, and studies used TRUS and/or DRE or IPSS alone [93].  
 
Studies included in our meta-analysis used the same laboratory parameters and 
equipment for blood and urine analysis. Prostate volume (PV) was used as a reliable 
measurement of LUTS and transrectal ultrasonography (TRUS) was considered more accurate 
than digital rectal examination (DRE) [94]. Confounding factors were identified and adjusted 
for: age; sex; smoking; alcohol consumption; sexual activity; UTI's or infections; 
constipation; exercise; drug intake; race; menopause. Confounders were adjusted for using 
logistical regression analysis [10,63,66,68], multivariate analysis  
[24,25,34,46,51,52,77,82], and sensitivity analysis [22]. Restrictions in design were also 
performed for age and sex; patients were also stratified according to age [22], menopause 
[57], or smoking status. Akin et al. (2016) used Receiver Operating Curves (ROC) and 
calculated area under curve (AUC) for OAB and WC (AUC 0.72 cm2, 95% CI 0.65-0.79, p < 
0.001) [22]; this produced highly sensitive and specific cut-off values to determine OAB 
presence (WC 98.5cm). MetS criteria often included gender-specific and race-specific BMI 
and WC cut-offs for obesity. The exclusion criteria included patients with neurological 
disorders; depression; antidepressant use; anticholinergic medication use; diuretics; 
bladder or prostate cancer; UTI; SUI; urinary symptoms since childhood [22]. [10,63,66,68] 
 
The strengths of our study include a clear objective and inclusion/exclusion criteria; not 
limited by sample size, follow-up period, length of intervention, or setting. We performed 
an extensive search of MEDLINE, SCOPUS, CENTRAL, and clinicaltrials.gov; reference lists of 
selected articles and other literature sources were also searched to ensure a comprehensive 
search of sources. Each study was screened by two independent reviewers; conflicts were 
resolved by a third reviewer. Data extraction was reviewed by a second reviewer. We have 
included a PRISMA flow-chart with reasons for exclusion of studies; the list of excluded 
studies (and conflicts) is available on Covidence. We included a table of eligible studies, 
detailed summaries, and characteristics. We performed a quality assessment (NOS) for each 
study included in our study (Table 1). Our current meta-analysis on TPV and MetS (k = 30, n 
= 22206) indicated significant results, albeit heterogeneity was relatively high (Fig. 3). 
Furthermore, a robust method with Sidik Jonkman estimation and Hartung Knapp 
adjustment was used to avoid type I error (false positives) in obtained results and to control 
for possible uncertainty due to heterogeneity. Additionally, a meta-regression analysis was 
conducted to address the resultant high heterogeneity; there was no significance in 
predictors being associated with effect sizes (Fig. 4 A-C; Table 3-7). Furthermore, an Egger's 
test of the intercept indicated no funnel plot asymmetry (Fig. 4 D); publication bias was not 
present. We performed a risk of bias assessment using the QUIPS tool and generated a graph 
(Fig. 5; Table 8).  
 
Most previous studies did not record and adjust for all confounders. Not all studies 
excluded covariates, e.g., neuropathy [44,60]. In diabetic patients, hyperglycaemia can 
result in small nerve fiber damage, known as neuropathy. This disorder can lead to an array 
of urological conditions including urgency, incontinence, incomplete emptying, UTI’s, and 
ED. Diabetes can also cause uropathy, which is when there is an obstruction in the urinary 
tract; this results in bladder disorders, recurrent UTI’s, and sexual dysfunction [95]. 
Oxidative damage can also cause a loss of bladder sensation [96]. Patients with neuropathy 
would be more likely to report worse LUTS symptoms and quality of life scores. In women, 
diabetic neuropathy was significantly associated with LUTS [97]. In men, prostatic growth is 
stimulated by elevated activity of the sympathic nerve, which is caused by elevated insulin 
levels  [98]. Studies did not always collect data on comorbidities such as cardiovascular 
disease or T2D [35]. Patients with diabetes have been shown to have higher incidences of 
DO and patients also tend to be older, which is another factor that increases the likelihood 
of developing LUTS [99,100]. Additionally, the following confounding factors could also lead 
to a variation in results. At binary logistic regression, OAB significantly correlated (p<0.001) 
with duration of menopausal >5 years (OR 25.7; 95% CI 5.82-113.72); parity more than twice 
(OR 27.94; 95% CI 8.25-94.6); previous gynaecological surgery (OR 33.04; 95% CI 8.78-124.38)  
[101]. Moderate to severe LUTS incidence was increased two-fold in men aged 70-79 (OR 
2.11, 95% CI 1.32-3.38) compared to other age groups  [102]. OAB was linearly associated 
with asthma (p = 0.001), bladder or prostate cancer (p = 0.001), and neurological conditions 
(stroke; Parkinson’s disease; multiple sclerosis) (p<0.001) [103]. Major adverse cardiac 
events (MACE), such as acute myocardial infarction, were positively associated with 
moderate-severe LUTS (OR 2.38; 95% CI 2.56-3.07; p<0.001)  [104]. Alcohol consumption >72 
g/day caused close to a third-fold increased risk of moderate-severe LUTS (OR 2.96, 95% CI 
1.61-5.44). History of STIs was also a risk factor (OR 1.50, 95% CI 1.08-2.07). Vigorous 
physical activity negatively correlated with incidence of moderate-severe LUTS (OR 0.61, 
95% CI 0.44-0.85) [102]. Zhu et al. (2019) negatively correlated OAB with employment status 
(OR 0.64, 95% CI 0.46–0.90). However, a meta-analysis by Zhu et al. (2019) also found no 
significant association between OAB and the following: menopause, sex, vaginal delivery, 
educational level, parity, race, marital status, smoking, and alcohol consumption [105]. 
 
Also, multiple studies were cross-sectional, which cannot account for temporal 
relationships between MetS and LUTS. Retrospective studies rely on data  previously 
collected; assessment of MetS and LUTS could not be controlled (Table 1). Furthermore, 
nocturia is self-reported; data rely on patients accurately recording their symptoms [35]. 
IPSS also relies on self-reporting of symptoms, an assessment which although validated, can 
be subjective; the LUTS group may have been able to recall and report their symptoms 
better compared to control subjects (memory bias). IPSS also has high variability [106]; 
BPH/LUTS symptoms are not constant. Most studies selected patients from a single 
institution, and samples were relatively small.  
Selecting patients from a specialist urology clinic can result in more severe presentations 
of LUTS. This is clearly at variance compared with the general population prevalence of 
severe LUTS. This was likely due to a referral bias as patients included in this meta-analysis 
were referred to a specialist urology clinic from wider region; cases with milder symptoms 
were probably managed more locally (referral bias). Patients attending these clinics were 
older, which is a risk factor for LUTS and MetS. Ageing increases the risk of developing 
obesity, T2D, hypertension, insulin resistance, and dyslipidaemia. Participants were mostly 
men. Additionally, asymptomatic control groups were not always included, and many studies 
did not include follow-up data. LUTS and MetS criteria were also highly heterogenous; this 
made it difficult to compare studies. According to WHO, American Heart Association (AHA), 
National Heart, Lung, and Blood Institute (NHLBI), and International Diabetes Federation 
(IDF), the waist circumference cut-offs for MetS for Caucasian men and women are ≥102 cm 
and ≥88 cm respectively. WHO and IDF have lower cut-offs for Asian men and women: ≥90 
cm and ≥80 cm respectively. The Japanese Obesity Society has an even lower cut-off for 
Asian men (≥85 cm) and a slightly higher cut-off for Asian women (≥90 cm) [1]. 
Results rely on the population included in a study, the prevalence of MetS, obesity, and 
LUTS in a sample, and the smoking status of individuals. In randomised control trials (RCTs), 
the effect of MetS components on LUTS is unclear because taking a random sample of men 
and women in the community does mean disorders of the uropoietic system will be present 
in the sample [13,42,46]. Furthermore, all RCTs are hypothetically designed for sample 
following a power calculation with 95% CI (p = 0.05). Even if results are significant, there is 
a 5% chance they are due to chance. Even though PV is associated with LUTS, some studies 
did not collect data concerning PV [66,67,83]. Most studies defined general obesity as BMI 
≥30 kg/m2, whilst some studies included overweight participants (BMI 25-29 kg/m2). 
According to WHO (1999), BMI ≥25 kg/m2 indicates overweight and BMI ≥30 kg/m2 indicates 
obesity [107]. This classification was intended for international use; however, the 
classification was revised given that high rates of T2D and cardiovascular risk factors were 
reported in Asian populations with an average BMI below 25kg/m2, below the WHO cut-off 
for ‘overweight’ [108]. BMI does not take into account muscle mass, and percentage body 
fat and BMI can differ according to age, sex, and ethnicity. In addition to using IPSS to 
measure symptoms of LUTS and BPH, TRUS should be used to accurately measure total 
prostate volume. Metabolic syndrome should be carefully managed when treating larger 
total prostate volumes in individuals with LUTS and BPH. More studies are required to 
determine the role of metabolic syndrome in prostate inflammation and enlargement. 
Improved study designs and homogenised samples led by hypothesis driven ideas are 
required. Future research should focus on the development of multicentre, multinational 
controlled trials with accurate definitions of MetS and LUTS. Recruiting from specialist 
centres and clinics is a better option than randomised control trials as it ensures that the 
sample contains individuals with LUTS and MetS. Specialists will also diagnose LUTS and MetS 
more accurately. Specialist urologists should administer questionnaires to reduce error. 
Additionally, all MetS components should be investigated and asymptomatic groups should 
be included. A more patient-specific method of measuring LUTS severity is also needed. 
Combining measurements of LUTS, QOL, and overall health status may increase specificity 
and sensitivity  [109]. TRUS should be used to measure TPV and LUTS. Confidence intervals 
above 95% would be ideal. More research into other uropoietic disorders especially on a 
genetic and molecular level. More data on the inflammatory markers involved is essential 
in confirming the role of MetS on inflammatory uropoietic disorders. 
5. CONCLUSION  
The present meta-analysis indicated no significant association between metabolic 
syndrome, or its components, and lower urinary tract symptoms. This is likely due to 
significant heterogeneity of methods used to evaluate LUTS symptoms in the studies we 
included. Regarding total prostate volume and metabolic syndrome, a significant association 
was noted in our study and is consistent with other studies in this field. Obesity, large waist 
circumference, hypertension, hyperinsulinaemia, dyslipidaemia, hypercholesterolaemia, 
and hypertriglyceridemia have been associated with worse symptoms of uropoietic disorders 
at multivariate analysis. Interventions aimed at weight loss including behavioural 
modification, obesity pharmacotherapy and obesity surgery are recommended and should 
be at the forefront of management of patients with MetS and disorders of the uropoietic 
system.  
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